IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies

Jennifer L. Ingram, Monica Kraft

Research output: Contribution to journalReview article

159 Citations (Scopus)

Abstract

Decades of research in animal models have provided abundant evidence to show that IL-13 is a key TH2 cytokine that directs many of the important features of airway inflammation and remodeling in patients with allergic asthma. Several promising focused therapies for asthma that target the IL-13/IL-4/signal transducer and activator of transcription 6 pathway are in development, including anti-IL-13 mAbs and IL-4 receptor antagonists. The efficacy of these new potential asthma therapies depends on the responsiveness of patients. However, an understanding of how IL-13-directed therapies might benefit asthmatic patients is confounded by the complex heterogeneity of the disease. Recent efforts to classify subphenotypes of asthma have focused on sputum cellular inflammation profiles, as well as cluster analyses of clinical variables and molecular and genetic signatures. Researchers and clinicians can now evaluate biomarkers of TH2-driven airway inflammation in asthmatic patients, such as serum IgE levels, sputum eosinophil counts, fraction of exhaled nitric oxide levels, and serum periostin levels, to aid decision making in clinical trials and drug development and to identify subsets of patients who might benefit from therapies. Although it is unlikely that these therapies will benefit all asthmatic patients with this heterogeneous disease, advances in understanding asthma subphenotypes in relation to clinical variables and TH2 cytokine responses offer the opportunity to improve the efficacy and safety of proposed therapies for asthma.

Original languageEnglish (US)
Pages (from-to)829-842
Number of pages14
JournalJournal of Allergy and Clinical Immunology
Volume130
Issue number4
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Interleukin-13
Asthma
Phenotype
Inflammation
Sputum
Therapeutics
STAT6 Transcription Factor
Interleukin-4 Receptors
Cytokines
Airway Remodeling
Serum
Eosinophils
Interleukin-4
Immunoglobulin E
Cluster Analysis
Molecular Biology
Decision Making
Nitric Oxide
Animal Models
Biomarkers

Keywords

  • Asthma
  • Biomarkers
  • Eosinophils
  • Fraction of exhaled nitric oxide
  • IgE
  • IL-13
  • Periostin
  • Phenotypes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

IL-13 in asthma and allergic disease : Asthma phenotypes and targeted therapies. / Ingram, Jennifer L.; Kraft, Monica.

In: Journal of Allergy and Clinical Immunology, Vol. 130, No. 4, 10.2012, p. 829-842.

Research output: Contribution to journalReview article

@article{a40d8af483ed4c0ab3328213dc6a3f09,
title = "IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies",
abstract = "Decades of research in animal models have provided abundant evidence to show that IL-13 is a key TH2 cytokine that directs many of the important features of airway inflammation and remodeling in patients with allergic asthma. Several promising focused therapies for asthma that target the IL-13/IL-4/signal transducer and activator of transcription 6 pathway are in development, including anti-IL-13 mAbs and IL-4 receptor antagonists. The efficacy of these new potential asthma therapies depends on the responsiveness of patients. However, an understanding of how IL-13-directed therapies might benefit asthmatic patients is confounded by the complex heterogeneity of the disease. Recent efforts to classify subphenotypes of asthma have focused on sputum cellular inflammation profiles, as well as cluster analyses of clinical variables and molecular and genetic signatures. Researchers and clinicians can now evaluate biomarkers of TH2-driven airway inflammation in asthmatic patients, such as serum IgE levels, sputum eosinophil counts, fraction of exhaled nitric oxide levels, and serum periostin levels, to aid decision making in clinical trials and drug development and to identify subsets of patients who might benefit from therapies. Although it is unlikely that these therapies will benefit all asthmatic patients with this heterogeneous disease, advances in understanding asthma subphenotypes in relation to clinical variables and TH2 cytokine responses offer the opportunity to improve the efficacy and safety of proposed therapies for asthma.",
keywords = "Asthma, Biomarkers, Eosinophils, Fraction of exhaled nitric oxide, IgE, IL-13, Periostin, Phenotypes",
author = "Ingram, {Jennifer L.} and Monica Kraft",
year = "2012",
month = "10",
doi = "10.1016/j.jaci.2012.06.034",
language = "English (US)",
volume = "130",
pages = "829--842",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - IL-13 in asthma and allergic disease

T2 - Asthma phenotypes and targeted therapies

AU - Ingram, Jennifer L.

AU - Kraft, Monica

PY - 2012/10

Y1 - 2012/10

N2 - Decades of research in animal models have provided abundant evidence to show that IL-13 is a key TH2 cytokine that directs many of the important features of airway inflammation and remodeling in patients with allergic asthma. Several promising focused therapies for asthma that target the IL-13/IL-4/signal transducer and activator of transcription 6 pathway are in development, including anti-IL-13 mAbs and IL-4 receptor antagonists. The efficacy of these new potential asthma therapies depends on the responsiveness of patients. However, an understanding of how IL-13-directed therapies might benefit asthmatic patients is confounded by the complex heterogeneity of the disease. Recent efforts to classify subphenotypes of asthma have focused on sputum cellular inflammation profiles, as well as cluster analyses of clinical variables and molecular and genetic signatures. Researchers and clinicians can now evaluate biomarkers of TH2-driven airway inflammation in asthmatic patients, such as serum IgE levels, sputum eosinophil counts, fraction of exhaled nitric oxide levels, and serum periostin levels, to aid decision making in clinical trials and drug development and to identify subsets of patients who might benefit from therapies. Although it is unlikely that these therapies will benefit all asthmatic patients with this heterogeneous disease, advances in understanding asthma subphenotypes in relation to clinical variables and TH2 cytokine responses offer the opportunity to improve the efficacy and safety of proposed therapies for asthma.

AB - Decades of research in animal models have provided abundant evidence to show that IL-13 is a key TH2 cytokine that directs many of the important features of airway inflammation and remodeling in patients with allergic asthma. Several promising focused therapies for asthma that target the IL-13/IL-4/signal transducer and activator of transcription 6 pathway are in development, including anti-IL-13 mAbs and IL-4 receptor antagonists. The efficacy of these new potential asthma therapies depends on the responsiveness of patients. However, an understanding of how IL-13-directed therapies might benefit asthmatic patients is confounded by the complex heterogeneity of the disease. Recent efforts to classify subphenotypes of asthma have focused on sputum cellular inflammation profiles, as well as cluster analyses of clinical variables and molecular and genetic signatures. Researchers and clinicians can now evaluate biomarkers of TH2-driven airway inflammation in asthmatic patients, such as serum IgE levels, sputum eosinophil counts, fraction of exhaled nitric oxide levels, and serum periostin levels, to aid decision making in clinical trials and drug development and to identify subsets of patients who might benefit from therapies. Although it is unlikely that these therapies will benefit all asthmatic patients with this heterogeneous disease, advances in understanding asthma subphenotypes in relation to clinical variables and TH2 cytokine responses offer the opportunity to improve the efficacy and safety of proposed therapies for asthma.

KW - Asthma

KW - Biomarkers

KW - Eosinophils

KW - Fraction of exhaled nitric oxide

KW - IgE

KW - IL-13

KW - Periostin

KW - Phenotypes

UR - http://www.scopus.com/inward/record.url?scp=84869100349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869100349&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2012.06.034

DO - 10.1016/j.jaci.2012.06.034

M3 - Review article

C2 - 22951057

AN - SCOPUS:84869100349

VL - 130

SP - 829

EP - 842

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -